| abstract |
the present invention relates to a laminin receptor peptide for use in the treatment of amyotrophic lateral sclerosis (it), which is also known as motor neuron disease (dnm) and can include frontotemporal dementia (dft). the invention also encompasses the laminin receptor peptide, nucleic acids encoding the laminin receptor peptide, vectors comprising the nucleic acids and compositions comprising the laminin receptor peptide. |